Abo Bibliothek: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Erscheint 4 Ausgaben pro Jahr

ISSN Druckformat: 0731-8898

ISSN Online: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Potentiation of the Photodynamic Action of Hypericin

Volumen 27, Ausgabe 1, 2008, pp. 23-33
DOI: 10.1615/JEnvironPatholToxicolOncol.v27.i1.30
Get accessGet access

ABSTRAKT

Hypericin (HY) is an interesting photosensitizer with dark activity and photodynamic therapy (PDT) effects via p53-independent pathway. In photodynamic diagnosis (PDD) of bladder cancer using HY, very high sensitivity and specificity were reported, in comparison with its counterpart, 5-aminolevulinic acid (5-ALA). HY was tested for the detection of human gastric cancer. It was also studied for treating some cancers and age-related macular degeneration and showed some promising findings. Several strategies to enhance the efficacy of HY-PDD and HY-PDT are reviewed. Using fractionated light dosing, fractionated drug dosing, hyperthermia, adjuvants such as oxygen carrier/antiangiogenesis, chemical modifications, and formulation approaches to enhance the PDT effects of HY are topics of this review. Despite cutting-edge technology approach such as preparing transferring-mediated targeting HY liposomes and nanoparticles of HY, such preparations did not always offer the desired enhanced treatment effects. It turns out that simple solutions of HY, especially those prepared without using plasma protein, were more successful in enhancing the delivery of HY for in vitro and in vivo systems. Thus, the HY-PDT with these formulations performed better. It is anticipated that HY-PDD and HY-PDT can be enhanced and optimized with the right combination of light dosimetry and drug dose in an effective formulation containing a suitable adjuvant. Hyperoxygenation and hyperthermia can also be used to further enhance the efficacy of HY-PDT.

REFERENZIERT VON
  1. Yarnell Eric, Abascal Kathy, Potential of Herbs as Clinical Photosensitizers, Alternative and Complementary Therapies, 18, 4, 2012. Crossref

  2. Gándara L., Sandes E., Di Venosa G., Prack Mc Cormick B., Rodriguez L., Mamone L., Batlle A., Eiján A.M., Casas A., The natural flavonoid silybin improves the response to Photodynamic Therapy of bladder cancer cells, Journal of Photochemistry and Photobiology B: Biology, 133, 2014. Crossref

  3. Li Tinghui, Deng Hong, Zhao Jingquan, Gu Ying, Elsinochrome A photosensitizers: Alternative drugs for photodynamic therapy, Journal of Innovative Optical Health Sciences, 08, 01, 2015. Crossref

  4. Larisch Patrick, Verwanger Thomas, Linecker Marina, Krammer Barbara, The interrelation between a pro-inflammatory milieu and fluorescence diagnosis or photodynamic therapy of human skin cell lines, Photodiagnosis and Photodynamic Therapy, 11, 2, 2014. Crossref

  5. Olivo Malini, Fu Chit Yaw, Raghavan Vijaya, Lau Weber Kam On, New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies, Annals of Biomedical Engineering, 40, 2, 2012. Crossref

  6. Wang Shengpeng, Chen Meiwan, Zhou Qi Tony, Chan Hak-Kim, NOVEL FORMULATIONS AND DRUG DELIVERY SYSTEMS FOR PHYTOTHERAPIES, in Phytotherapies, 2015. Crossref

  7. Sanovic Renata, Verwanger Thomas, Hartl Arnulf, Krammer Barbara, Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma, Photodiagnosis and Photodynamic Therapy, 8, 4, 2011. Crossref

  8. Ware William R., P450 CYP1B1 mediated fluorescent tumor markers: A potentially useful approach for photodynamic therapy, diagnosis and establishing surgical margins, Medical Hypotheses, 72, 1, 2009. Crossref

  9. Ritz R., Daniels R., Noell S., Feigl G.C., Schmidt V., Bornemann A., Ramina K., Mayer D., Dietz K., Strauss W.S.L., Tatagiba M., Hypericin for visualization of high grade gliomas: First clinical experience, European Journal of Surgical Oncology (EJSO), 38, 4, 2012. Crossref

  10. Lüthi Martin, Besic Gyenge Emina, Engstrüm Mathias, Bredell Marius, Grätz Klaus, Walt Heinrich, Gmür Rudolf, Maake Caroline, Hypericin- and mTHPC-mediated photodynamic therapy for the treatment of cariogenic bacteria, Medical Laser Application, 24, 4, 2009. Crossref

  11. Debele Tilahun, Peng Sydney, Tsai Hsieh-Chih, Drug Carrier for Photodynamic Cancer Therapy, International Journal of Molecular Sciences, 16, 9, 2015. Crossref

  12. Li Xingshu, Zheng Bing-De, Peng Xiao-Hui, Li Song-Zi, Ying Jia-Wen, Zhao Yuanyuan, Huang Jian-Dong, Yoon Juyoung, Phthalocyanines as medicinal photosensitizers: Developments in the last five years, Coordination Chemistry Reviews, 379, 2019. Crossref

  13. Saw Constance L. L., Heng Paul W. S., Hypericin, in Encyclopedia of Cancer, 2017. Crossref

  14. Poiroux Guillaume, Barre Annick, Rougé Pierre, Benoist Hervé, Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy, Current Cancer Drug Targets, 19, 5, 2019. Crossref

  15. Camargo Vinicius G., Zanuto Vitor S., Astrath Nelson G. C., Caetano Wilker, Hioka Noboru, Pereira Paulo C. S., Gonçalves Renato S., Lukasievicz Gustavo V. B., Herculano Leandro S., Malacarne Luis C., From Protohypericin to Hypericin: Photoconversion Analysis Using a Time-Resolved Thermal Lens Technique, Applied Spectroscopy, 73, 8, 2019. Crossref

  16. Saw Constance L. L., Heng Paul W. S., Hypericin, in Encyclopedia of Cancer, 2015. Crossref

  17. Sztandera Krzysztof, Gorzkiewicz Michał, Klajnert‐Maculewicz Barbara, Nanocarriers in photodynamic therapy—in vitro and in vivo studies, WIREs Nanomedicine and Nanobiotechnology, 12, 3, 2020. Crossref

  18. Wang Zhao, Sun Qianqian, Liu Bin, Kuang Ye, Gulzar Arif, He Fei, Gai Shili, Yang Piaoping, Lin Jun, Recent advances in porphyrin-based MOFs for cancer therapy and diagnosis therapy, Coordination Chemistry Reviews, 439, 2021. Crossref

  19. Deng Huaxiang, Liang Xinxin, Liu Jinbin, Zheng Xiaohui, Fan Tai-Ping, Cai Yujie, Advances and perspectives on perylenequinone biosynthesis, Frontiers in Microbiology, 13, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain